Pfizer Studies Robust Earnings, Raises 2019 Guidance – The Wall Street Journal

Pfizer Inc. reported solid third-quarter earnings as its aim on bringing new prescription medicines to industry showed symptoms of having to pay off.

The drugmaker’s earnings have been boosted by more recent items, these types of as breast-cancer treatment Ibrance, which had earnings of $1.3 billion, up 25%. The $156 million in profits of Vyndaqel, a drug permitted in Might that treats people with a rare affliction that can guide to heart failure, also topped analyst expectations.

Examine A lot more

Add Comment